H Yki-Jarvinen - New England Journal of Medicine, 2004 - content.nejm.org Insulin resistance both precedes and predicts type 2 diabetes mellitus. 1
Although exercise and weight loss ameliorate insulin resistance and may in some
cases prevent or delay onset of the disease, 2 therapy that combats insulin ... Cited by 834 - Related articles - BL Direct - All 6 versions
- ►infodiabetes.it [PDF] PD Home, SJ Pocock, H Beck-Nielsen, R … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1726–1735 DOI 10.1007/s00125-005-1869-1 ARTICLE
PD Home . SJ Pocock . H. Beck-Nielsen . R. Gomis . M. Hanefeld . H. Dargie . ... Cited by 147 - Related articles - BL Direct - All 5 versions
- ►aspetjournals.org M Bae, BJ Song - Molecular pharmacology, 2003 - ASPET The peroxisome proliferator-activated receptor agonist troglitazone (TRO) was
used for treatment of non-insulin-dependent diabetes until its removal from the
market because of its severe hepatotoxicity. However, the mechanism for its ... Cited by 67 - Related articles - BL Direct - All 5 versions
MC Riddle - Endocrinology and metabolism clinics of North America, 2005 - Elsevier We have long known, but now understand more fully that type 2 diabetes is
common, complex, and as treated presently, leads to severe medical consequences.
In type 1 diabetes, hyperglycemia is the leading cause of harm. In type 2 ... Cited by 67 - Related articles - All 3 versions
A Rubenstrunk, R Hanf, DW Hum, JC Fruchart, … - BBA-Molecular and Cell Biology of Lipids, 2007 - Elsevier Because of their wide range of actions on glucose homeostasis, lipid metabolism
and vascular inflammation, peroxisome proliferator-activated receptors (PPARs)
are promising targets for the development of new drugs for the treatment of ... Cited by 55 - Related articles - All 3 versions
WL Isley - eds, 2003 - informahealthcare.com Thiazolidinediones are insulin sensitisers now widely used for the treatment of
Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone,
was removed from the market worldwide after approximately 3 years of use ... Cited by 53 - Related articles - BL Direct - All 9 versions
- ►annals.org [PDF] KG Tolman, V Fonseca, MH Tan, A Dalpiaz - Annals of internal medicine, 2004 - Am Coll Physicians Diabetes mellitus is the fifth leading cause of death in the United States; 17
million people are affected. Liver disease is one of the leading causes of death
in persons with type 2 diabetes. The standardized mortality rate for death ... Cited by 51 - Related articles - All 5 versions
